Abstract
Purpose :
A number of mininally invasive glaucoma surgery (MIGS) devices have recently become available for the treatment of Primary Open Angle Glaucoma, with varying levels of evidence regarding safety and efficacy.
The CyPass microstent is a 6mm polyimide tube that is inserted under gonioscopic visualisation into the suprachoroidal space. We performed a prospective efficacy and safety analysis of the CyPass suprachoroidal Micro-Stent following its introduction in a tertiary referral glaucoma service in London, United Kingdom.
Methods :
Data was collected prospectively on all CyPass implants carried out from September 2017 including preoperative IOP, visual acuity (V/A) and number of glaucoma medications. V/A, IOP and medications started was measured at all subsequent follow up visits, along with documented complications.
Results :
10 eyes received CyPass implants with 2 combined with routine phacoemulsification. 7/10 (70%) of patients were Afro-Caribbean and 3/10 (30%) were Caucasian. Mean preoperative IOP was 21mmHg (SD 5.3, range 15-30) on an average of 3.1 drops (SD 0.99). Mean IOP at day 1 was 13.3mmHg (SD 4.3, range 6-18). This IOP decrease was sustained at week 4 at 13.4mmHg (SD 2.7, range 10-16) representing a 36.2% reduction from preoperative IOP, with only 1 patient restarted on IOP lowering medication. Adverse effects of CyPass implantation were limited to minor haemorrhage resulting in microscopic hyphaema. There were no episodes of hypotony.
Conclusions :
These early data demonstrate a good initial IOP lowering effect of the CyPass implant with excellent safety profile. Further follow up will determine whether this effect is sustained over the longer term.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.